WALTHAM, Mass.--(BUSINESS WIRE)--Repligen Corporation (NASDAQ: RGEN) today provided an update on corporate progress in the development of SecreFlo™ for pancreatic imaging, in its bioprocessing business and in the development of its CNS product candidates during Q2 FY2012, ending September 30, 2011.
